Journal of Pharmacy And Bioallied Sciences
Journal of Pharmacy And Bioallied Sciences Login  | Users Online: 1330  Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size 
    Home | About us | Editorial board | Search | Ahead of print | Current Issue | Past Issues | Instructions | Online submission




 
 Table of Contents  
ORIGINAL/BRIEF
Year : 2012  |  Volume : 4  |  Issue : 5  |  Page : 1-3  

Development of siRNA lipoplexes for intracellular delivery in lung cancer cells


Department of Pharmacy, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara, Gujarat, India

Date of Web Publication21-Mar-2012

Correspondence Address:
N Khatri
Department of Pharmacy, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Kalabhavan, Vadodara, Gujarat
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0975-7406.94115

Rights and Permissions
   Abstract 

Lung cancer occurrence throughout the world and its unsatisfactory treatment has drawn significant attention from many medical agencies. A genomic approach utilizing siRNA against target gene may resolve this problem. Present investigation includes siRNA lipoplex formulation and its in-vitro characterisation in lung cancer cell line for intracellular uptake and cytotoxicity. Accumulation of siRNA inside the cell as well as less cytotoxicity of prepared carrier system signifies potential of prepared siRNA lipoplex in the treatment of lung cancer.

Keywords: Cytotoxicity, gel electrophoresis, gene targeting, liposomes


How to cite this article:
Khatri N, Misra A. Development of siRNA lipoplexes for intracellular delivery in lung cancer cells. J Pharm Bioall Sci 2012;4, Suppl S1:1-3

How to cite this URL:
Khatri N, Misra A. Development of siRNA lipoplexes for intracellular delivery in lung cancer cells. J Pharm Bioall Sci [serial online] 2012 [cited 2020 Aug 9];4, Suppl S1:1-3. Available from: http://www.jpbsonline.org/text.asp?2012/4/5/1/94115

Long term exposure to tobacco smoke is the main cause for more than 1.5 million deaths worldwide yearly. [1] India accounts 10% of total world's lung cancer incidents. At present lung cancer is treated with intravenous administration of chemotherapeutic agents, but lack of selectivity of these drug molecules cause lethal actions to non cancerous cells. [2] This provides impulsion to carry out a research for effective and safe treatment of lung cancer. Small interfering RNA (siRNA) is a duplex of 19-23 nucleotide base pairs which specifically slices target mRNA and hence expression of a protein can be inhibited. [3] Present investigation utilizes the siRNA macromolecule, complexed with liposomes, for effective treatment of lung cancer.


   Materials and Methods Top


All phospholipids and cholesterol were purchased from Lipoid, Germany. All siRNAs were purchased from MWG-Europhins, Germany. FAM-NC-siRNA and NC-siRNA were obtained from Gene Pharma, China. All other chemicals and reagents used were of Analytical grades/HPLC grade/Biological grades. A-549 cell line was obtained from NCCS, Pune.

Formulation

siRNA lipoplexes were prepared by incubating siRNA with preformed liposomes. Briefly, liposomes were prepared using mixture of positively charged lipid, endosomolytic lipid, neutral phospholipid, cholesterol and methoxy polyethylene glycol Distearoyl phosphatidyl ethanolamine. All lipids were dissolved in chloroform and dry lipid film was obtained by stripping all organic solvent. Hydration was performed using RNAase free water. Prepared liposomes were size reduced by probe sonication and incubated with siRNA different nitrogen to phosphate charge ratio.

Agarose gel electrophoresis

Formation of lipoplex and complete complexation of siRNA with liposomes were confirmed using agarose gel electrophoresis. siRNA and liposomes were loaded onto agarose gel at different N/P ratio and documented in gel documentation system using Biorad XR + model (Bio-Rad, USA).

Particle size and zeta potential

Prepared lipoplexes were characterized for particle size, size distribution [Figure 1] using and zeta potential using Malvern Zeta Sizer instrument (Malvern, USA).
Figure 1: Particle size distribution

Click here to view


In-vitro cell line studies

To access the potential of prepared lipoplexes as a non-viral vector for siRNA delivery inside the cell, studies were carried out in lung cancer cell line, A-549.

Flow cytometry

FAM labelled Negative control siRNA was used for intracellular uptake study in A-549 cell line. Cells were seeded in 96 well plates (5000 cells/well) 24 hrs before siRNA treatment. After 24 hrs 100nM siRNA lipoplexes were added to each well in serum and antibiotic free media. After 5 hrs of incubation, media was replaced with serum and antibiotic free fresh media. Cells were trypsinized and analysed for mean fluorescence activity using fluorescence activated cell sorter (FACS-BD-AriaIII, Becton-Dickinson, USA).

Cell cytotoxicity (MTT assay)

Cells were seeded in 96 well plate at a density of 5000 cells per well. After 24 hrs cells were treated with 100nM of NC-siRNA and further processed for MTT assay. Cell viability was measured colorimetrically using enzyme-linked immunosorbent assay plate reader (Biorad, USA) at a wavelength of 570 nm.


   Results and Discussion Top


Lipoplexes were prepared at different N/P ratio and characterized for complexation studies using Gel Electrophoresis. Lipoplexes above N/P=1.5 were found to be completely free of naked siRNA. This will prevent degradation of siRNA from nuclease enzyme in biological system. [4],[5] Particle size for optimal lipoplex was found to be 107.6 nm with 0.158 PDI value. Positive value for zeta potential was obtained due to involvement of charged lipids in the formulations. Zeta potential for optimized lipoplex was 12.9 mV [Figure 2]. Various lipoplex formulations were assessed for in-vitro cell line studies in A-549 cells and Lipofectamine TM was used as a positive control. There was a significant difference (P<0.05) in the uptake of siRNA, which were given in lipoplex form as compared to positive control [Figure 3].
Figure 2: Zeta potential

Click here to view
Figure 3: Cell uptake by FACS

Click here to view


This finding clearly shows potential of prepared formulation for intracellular delivery of siRNA. Cell viability was determined using MTT assay after 48 hrs. [Figure 2] shows cell viability after treatment with 100nM of siRNA in lipoplex form using blank sample as a negative control and Lipofectamine TM as positive control. Optimal formulation shows significantly more (P<0.05) cell viability as compared to Lipofectamine TM [Figure 4].
Figure 4: Cell cytotoxicity (MTT assay)

Click here to view



   Conclusion Top


siRNA lipoplex can be a potential non-viral delivery vector for intracellular delivery of nucleic acid molecules. Complete complexation ensures resistance from degradation by nucleases. Intracellular uptake of siRNA in lipoplex form and cell viability results signifies its potential for further development as a novel drug delivery vector. Although prepared siRNA lipoplexes have opened new vista for chemotherapeutics, concrete proof can only be attained after successful in-vivo studies in suitable animal models.


   Acknowledgement Top


Authors acknowledge the financial assistance from Department of Biotechnology (DBT) and TIFAC CORE in NDDS, Government of India, New Delhi for providing the research facilities to the team.

 
   References Top

1.Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.  Back to cited text no. 1
    
2.Egusquiaguirre SP, Igartua M, Hernandez RM, Pedraz JL. Nanoparticle delivery systems for cancer therapy: Advances in clinical and preclinical research. Clin Transl Oncol 2012;14:83-93.  Back to cited text no. 2
    
3.Kim D, Rossi J. RNAi mechanisms and applications. Biotechniques 2008;44:613-6.  Back to cited text no. 3
    
4.Paroo Z, Corey DR. Challenges for RNAi in vivo. Trends Biotechnol 2004;22:390-4.  Back to cited text no. 4
    
5.Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: Differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 2004;43:13348-56.  Back to cited text no. 5
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4]


This article has been cited by
1 Dicationic Surfactants with Glycine Counter Ions for Oligonucleotide Transportation
Zuzanna Pietralik,Andrzej Skrzypczak,Maciej Kozak
ChemPhysChem. 2016;
[Pubmed] | [DOI]
2 Gemini Surfactants Based on Bis-Imidazolium Alkoxy Derivatives as Effective Agents for Delivery of Nucleic Acids: A Structural and Spectroscopic Study
Zuzanna Pietralik,Zaneta Kolodziejska,Marek Weiss,Maciej Kozak,Heidar-Ali Tajmir-Riahi
PLOS ONE. 2015; 10(12): e0144373
[Pubmed] | [DOI]
3 The influence of novel gemini surfactants containing cycloalkyl side-chains on the structural phases of DNA in solution
Zuzanna Pietralik,Janet R. Kumita,Christopher M. Dobson,Maciej Kozak
Colloids and Surfaces B: Biointerfaces. 2015; 131: 83
[Pubmed] | [DOI]
4 siRNA Delivery to the lung: Whatęs new?
Olivia M. Merkel,Israel Rubinstein,Thomas Kissel
Advanced Drug Delivery Reviews. 2014; 75: 112
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
    Materials and Me...
    Results and Disc...
   Conclusion
   Acknowledgement
    References
    Article Figures

 Article Access Statistics
    Viewed1852    
    Printed87    
    Emailed0    
    PDF Downloaded89    
    Comments [Add]    
    Cited by others 4    

Recommend this journal